Novel treatment strategies for chronic myeloid leukemia

American Journal of Health-System Pharmacy

Volumn 63, Issue 23 SUPPL., 2006, Pages

  Fausel, Christopher A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antineoplastic agents; Dasatinib; Drug comparisons; Farnesyl transferase inhibitors; Imatinib; Leukemia; Mechanism of action; Neoplasm vaccines; Nilotinib; Research; Resistance; Site of action; Toxicity; Vaccines

Indexed keywords

4 METHYL N [3 (4 METHYL 1 IMIDAZOLYL) 5 (TRIFLUOROMETHYL)PHENYL] 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]BENZAMIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CANCER VACCINE; DASATINIB; IMATINIB; LONAFARNIB; N (2 CHLORO 6 METHYLPHENYL) 2 [6 [4 (2 HYDROXYETHYL) 1 PIPERAZINYL] 2 METHYL 4 PYRIMIDINYLAMINO] 5 THIAZOLECARBOXAMIDE; NILOTINIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; TIPIFARNIB; UNCLASSIFIED DRUG;

BLOOD TOXICITY; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GENERALIZED EDEMA; HEADACHE; HOT FLUSH; HUMAN; HYPOCALCEMIA; LIVER DYSFUNCTION; LUNG EDEMA; NAUSEA; NEUTROPENIA; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; RASH; SKIN TOXICITY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT INDICATION; TUMOR LYSIS SYNDROME; VOMITING;

EID: 33751566534     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060526     Document Type: Conference Paper

References (23)

1. Schindler T, Bornmann W, Pellicena P et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000; 289:1938-42.
2. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004; 11:35-43.
3. Weisberg E, Manley P, Mestan J et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006; 94:1765-9.
4. Lombardo LJ, Lee FY, Chen P et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47:6658-61.
5. Shah NP, Tran C, Lee FY et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305:399-401.
6. Roskoski R Jr. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Commun. 2004; 324:1155-64.
7. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006; 12:1398-401.
8. Tokarski JS, Newitt JA, Chang CY et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006; 66:5790-7.
9. O'Hare T, Walters DK, Stoffregen EP et al. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res. 2005; 11:6987-93.
10. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006; 354:2531-41.
11. Guilhot F, Apperley JF, Shah N. A Phase II Study of Dasatinib in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML) Who Are Resistant or Intolerant to Imatinib: First Results of the CA180005 'START-A' Study. Blood. 2005; 106:16a [abstract 39].
12. Ottmann OG, Martinelli G, Dombret H. A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The 'START-L' CA180015 Study. Blood. 2005; 106:17a [abstract 42].
13. Kantarjian H, Ottmann OG, Cortes J. AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph+ ALL). Blood. 2005; 106:15a [abstract 37].
14. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354:2542-51.
15. O'Quigley J, Shen LZ, Gamst A. Two-sample continual reassessment method. J Biopharm Stat. 1999; 9:17-44.
16. Pan J, Yeung SC. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res. 2005; 65:9109-12.
17. Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005; 23:6316-24.
18. Cortes J, Albitar M, Thomas D et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003; 101:1692-7.
19. Karp JE, Lancet JE, Kaufmann SH et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001; 97:3361-9.
20. Borthakur G, Kantarjian H, Daley G et al. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006; 106:346-52.
21. Kolb HJ, Schmid C, Barrett AJ et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004; 103:767-76.
22. Bonifazi F, de Vivo A, Rosti G et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001; 98:3074-81.
23. Reichardt VL, Brossart P. Current status of vaccination therapy for leukemias. Curr Hematol Rep. 2005; 4:73-6.